Shares of Delcath Systems DCTH fell 13.6% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 49.47% over the past year to ($0.96), which beat the estimate of ($0.99).
Revenue of $536,000 higher by 41.42% from the same period last year, which missed the estimate of $720,000.
Outlook
Delcath Systems hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Aug 10, 2021
Time: 08:30 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2475/42376
Recent Stock Performance
52-week high: $25.18
52-week low: $8.78
Price action over last quarter: down 4.09%
Company Overview
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
